Table 1.

Probable disease-causing variants and VUS

GeneVariantNo. of patientsNovel or previously-reported mutationProbable disease-causing variant or VUSBiologic significance
F5 (factor V) R506Q (factor V Leiden) Previously reported Probable disease-causing variant Thrombotic 
T887S Previously reported VUS Thrombotic 
R679Q Novel VUS Disruptive to protein structure 
F2 (prothrombin) G20210A (prothrombin gene mutation) Previously reported Probable disease-causing variant Thrombotic 
IVS6+5G>A Novel VUS Disruptive to protein structure 
PROS1 (PS) Y234C Previously reported Probable disease-causing variant Thrombotic 
P76L Previously reported VUS Unlikely to be significant 
R233K Previously reported VUS Thrombotic 
Homozygous S460P (Heerlen allele) Previously reported Probable disease-causing variant Thrombotic 
R40L Previously reported VUS Thrombotic 
PROC (PC) R57W Previously reported Probable disease-causing variant Thrombotic 
A301S Previously reported Probable disease-causing variant Thrombotic 
SERPINA10 (protein Z–dependent protease inhibitor) Q384R Previously reported VUS Disruptive to protein structure 
21_23 delCCT Novel VUS Unlikely to be significant 
W324X Previously reported VUS Disruptive to protein structure 
SERPINC1 (AT) S426W Novel Probable disease-causing variant Disruptive to protein structure 
D232N Novel VUS Disruptive to protein structure 
L131F Previously reported Probable disease-causing variant Thrombotic 
260 c.778_779insGAA Novel Probable disease-causing variant Disruptive to protein structure 
c.1153+5 G>C Novel Probable disease-causing variant Disruptive to protein structure 
SERPIND1 (heparin cofactor II) R468C Novel VUS Disruptive to protein structure 
SERPINE2 (protease nexin-1) M64T Previously reported VUS Uncertain 
SERPINF2 (α-2 antiplasmin) P451S Previously reported VUS Unlikely to be significant 
HABP2 (factor VII–activating protease) G534E (Marburg I) Previously reported Probable disease-causing variant Thrombotic 
E393Q (Marburg II) Previously reported VUS Disruptive to protein structure 
C533F Novel VUS Disruptive to protein structure 
S6I Novel VUS Uncertain 
THBD (thrombomodulin) P401L Novel VUS Disruptive to protein structure 
HRG (histidine-rich glycoprotein) R42Q Novel VUS Disruptive to protein structure 
JAK2 (Janus kinase 2) R1063H Previously reported Probable disease-causing variant Disruptive to protein structure 
SH2B3 (SH2B adaptor protein 3) V402M Previously reported VUS Disruptive to protein structure 
VWF (von Willebrand factor) P2063S Previously reported VUS Unlikely to be significant 
PLG (plasminogen) A494V Novel VUS Unlikely to be significant 
R490Q Novel VUS Unlikely to be significant 
TF (tissue factor) R343W Novel VUS Uncertain 
FGA (fibrinogen α-chain) E729Q Previously reported VUS Uncertain 
FGG (fibrinogen γ-chain) S245F Previously reported VUS Uncertain 
CALR (calreticulin) Y57C Previously reported VUS Uncertain 
ADAMTS13 (ADAM metallopeptidase with thrombospondin type 1 motif 13) C668R Novel VUS Uncertain 
ACE (angiotensin-converting enzyme) G354R Novel VUS Uncertain 
GeneVariantNo. of patientsNovel or previously-reported mutationProbable disease-causing variant or VUSBiologic significance
F5 (factor V) R506Q (factor V Leiden) Previously reported Probable disease-causing variant Thrombotic 
T887S Previously reported VUS Thrombotic 
R679Q Novel VUS Disruptive to protein structure 
F2 (prothrombin) G20210A (prothrombin gene mutation) Previously reported Probable disease-causing variant Thrombotic 
IVS6+5G>A Novel VUS Disruptive to protein structure 
PROS1 (PS) Y234C Previously reported Probable disease-causing variant Thrombotic 
P76L Previously reported VUS Unlikely to be significant 
R233K Previously reported VUS Thrombotic 
Homozygous S460P (Heerlen allele) Previously reported Probable disease-causing variant Thrombotic 
R40L Previously reported VUS Thrombotic 
PROC (PC) R57W Previously reported Probable disease-causing variant Thrombotic 
A301S Previously reported Probable disease-causing variant Thrombotic 
SERPINA10 (protein Z–dependent protease inhibitor) Q384R Previously reported VUS Disruptive to protein structure 
21_23 delCCT Novel VUS Unlikely to be significant 
W324X Previously reported VUS Disruptive to protein structure 
SERPINC1 (AT) S426W Novel Probable disease-causing variant Disruptive to protein structure 
D232N Novel VUS Disruptive to protein structure 
L131F Previously reported Probable disease-causing variant Thrombotic 
260 c.778_779insGAA Novel Probable disease-causing variant Disruptive to protein structure 
c.1153+5 G>C Novel Probable disease-causing variant Disruptive to protein structure 
SERPIND1 (heparin cofactor II) R468C Novel VUS Disruptive to protein structure 
SERPINE2 (protease nexin-1) M64T Previously reported VUS Uncertain 
SERPINF2 (α-2 antiplasmin) P451S Previously reported VUS Unlikely to be significant 
HABP2 (factor VII–activating protease) G534E (Marburg I) Previously reported Probable disease-causing variant Thrombotic 
E393Q (Marburg II) Previously reported VUS Disruptive to protein structure 
C533F Novel VUS Disruptive to protein structure 
S6I Novel VUS Uncertain 
THBD (thrombomodulin) P401L Novel VUS Disruptive to protein structure 
HRG (histidine-rich glycoprotein) R42Q Novel VUS Disruptive to protein structure 
JAK2 (Janus kinase 2) R1063H Previously reported Probable disease-causing variant Disruptive to protein structure 
SH2B3 (SH2B adaptor protein 3) V402M Previously reported VUS Disruptive to protein structure 
VWF (von Willebrand factor) P2063S Previously reported VUS Unlikely to be significant 
PLG (plasminogen) A494V Novel VUS Unlikely to be significant 
R490Q Novel VUS Unlikely to be significant 
TF (tissue factor) R343W Novel VUS Uncertain 
FGA (fibrinogen α-chain) E729Q Previously reported VUS Uncertain 
FGG (fibrinogen γ-chain) S245F Previously reported VUS Uncertain 
CALR (calreticulin) Y57C Previously reported VUS Uncertain 
ADAMTS13 (ADAM metallopeptidase with thrombospondin type 1 motif 13) C668R Novel VUS Uncertain 
ACE (angiotensin-converting enzyme) G354R Novel VUS Uncertain 

The biologic significance of each variant was categorized as “thrombotic,” “disruptive to protein structure,” “unlikely to be significant,” or “uncertain,” based on definitions in “Methods.”

Close Modal

or Create an Account

Close Modal
Close Modal